Celastrol inhibits colorectal cancer through TGF-β1/Smad signaling

• DOI: 10.2147/ott.s187817
• Publication Date: 2019-01-09T00:46:56Z
• Authors: Zhitao Jiang; Qianyu Cao; Guoliang Dai; Jianchun Wang; Chundi Liu; Lingyan Lv; Jinhuo Pan
• Keywords: Celastrol

Celastrol inhibits colorectal cancer through TGF-beta1/Smad signaling Zhitao Jiang,1,* Qianyu Cao,2,* Guoliang Dai,3 Jianchun Wang,1 Chundi Liu,1 Lingyan Lv,1 Jinhuo Pan4 1Department of Pharmacy Office, Zhangjiagang Hospital Traditional Chinese Medicine Affiliated to Nanjing University Medicine, Zhangjiagang, China; 2The First Clinical College, Nanjing, 3Department Pharmacology, 4College Pharmacy, China *These authors contributed equally this work Background: There are few clinical challenges associated with the treatment (CRC). Studies have shown that TGF-β plays a crucial role in CRC. Importantly, celastrol, major components root extract traditional herb Tripterygium wilfordii Hook F, has been inhibit growth, adhesion, and metastasis human CRC cells inhibition TGF-β1/Smad signaling.Materials methods: Real-time PCR Western blot tests were proceeded present TGF-β1, receptor type I (TGFβRI), II (TGFβRII), Smad2/3, p-Smad2/3, Smad4, glyceraldehyde-3-phosphate dehydrogenase expression colon cell samples.Results: Our results indicated celastrol can reduce levels TGFβRI, TGFβRII HCT116 SW620 cells. Furthermore, could also prevent increase Smad4 p-Smad2/3 cells.Conclusion: tumor growth might be promising therapeutic component against Keywords: cancer, Smad